These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 31565873)

  • 1. Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy.
    Liu J; Liu Y; Lin Y; Liang J
    Endocrinol Metab (Seoul); 2019 Sep; 34(3):215-225. PubMed ID: 31565873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS.
    Oh JM; Ahn BC
    Theranostics; 2021; 11(13):6251-6277. PubMed ID: 33995657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
    Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
    Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
    [No Abstract]   [Full Text] [Related]  

  • 4. Mechanisms of regulating NIS transport to the cell membrane and redifferentiation therapy in thyroid cancer.
    Cai X; Wang R; Tan J; Meng Z; Li N
    Clin Transl Oncol; 2021 Dec; 23(12):2403-2414. PubMed ID: 34100218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Tyrosine Kinase Inhibitor Can Augment Radioactive Iodine Uptake Through Endogenous Sodium/Iodide Symporter Expression in Anaplastic Thyroid Cancer.
    Oh JM; Baek SH; Gangadaran P; Hong CM; Rajendran RL; Lee HW; Zhu L; Gopal A; Kalimuthu S; Jeong SY; Lee SW; Lee J; Ahn BC
    Thyroid; 2020 Apr; 30(4):501-518. PubMed ID: 31928162
    [No Abstract]   [Full Text] [Related]  

  • 6. Post-translational Regulation of Radioactive Iodine Therapy Response in Papillary Thyroid Carcinoma.
    Amit M; Na'ara S; Francis D; Matanis W; Zolotov S; Eisenhaber B; Eisenhaber F; Weiler Sagie M; Malkin L; Billan S; Charas T; Gil Z
    J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 30053080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of ALK-Signaling Overcomes STRN-ALK-Induced Downregulation of the Sodium Iodine Symporter and Restores Radioiodine Uptake in Thyroid Cells.
    Nikitski AV; Condello V; Divakaran SS; Nikiforov YE
    Thyroid; 2023 Apr; 33(4):464-473. PubMed ID: 36585857
    [No Abstract]   [Full Text] [Related]  

  • 8. Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies.
    Liu YY; van der Pluijm G; Karperien M; Stokkel MP; Pereira AM; Morreau J; Kievit J; Romijn JA; Smit JW
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):617-24. PubMed ID: 16712662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NIS and epithelial-mesenchymal transition marker expression of circulating tumor cells for predicting and monitoring the radioactive iodine-131 therapy effect in differentiated thyroid cancers.
    Zheng L; Wang G; Guo W; Pan D; Xie L; He S; Luo C; Li H; Ran Y; Wu S; Liu F; Zhang X; Huang D
    Mol Biol Rep; 2019 Aug; 46(4):4201-4212. PubMed ID: 31147861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Outcomes of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers.
    Toro-Tobon D; Morris JC; Hilger C; Peskey C; Durski JM; Ryder M
    Thyroid; 2024 Jan; 34(1):70-81. PubMed ID: 37917101
    [No Abstract]   [Full Text] [Related]  

  • 11. Curcumin enhances the membrane trafficking of the sodium iodide symporter and augments radioiodine uptake in dedifferentiated thyroid cancer cells
    Zhang L; Xu S; Cheng X; Wu J; Wang X; Wu L; Yu H; Bao J
    Food Funct; 2021 Sep; 12(18):8260-8273. PubMed ID: 34323243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sinomenine Hydrochloride Promotes TSHR-Dependent Redifferentiation in Papillary Thyroid Cancer.
    Zhang J; Zhao A; Jia X; Li X; Liang Y; Liu Y; Xie X; Qu X; Wang Q; Zhang Y; Gao R; Yu Y; Yang A
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy.
    Liu Y; Wang J; Hu X; Pan Z; Xu T; Xu J; Jiang L; Huang P; Zhang Y; Ge M
    Drug Resist Updat; 2023 May; 68():100939. PubMed ID: 36806005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Inverse Agonist of Estrogen-Related Receptor Gamma, GSK5182, Enhances Na
    Singh TD; Lee JE; Son KH; Lee BR; Kim SK; Gulwani D; Sarangthem V; Jeon YH
    Cells; 2023 Feb; 12(3):. PubMed ID: 36766812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of miR-139-5p in radioiodine-resistant thyroid cancer.
    Pecce V; Sponziello M; Verrienti A; Grani G; Abballe L; Bini S; Annunziata S; Perotti G; Salvatori M; Zagaria L; Maggisano V; Russo D; Filetti S; Durante C
    J Endocrinol Invest; 2023 Oct; 46(10):2079-2093. PubMed ID: 36933170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiated thyroid cancer theranostics: radioiodine and beyond.
    Choudhury PS; Gupta M
    Br J Radiol; 2018 Nov; 91(1091):20180136. PubMed ID: 30260232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Redox Homeostasis in Thyroid Cancer: Implications in Na
    Cazarin J; Dupuy C; Pires de Carvalho D
    Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers.
    Dunn LA; Sherman EJ; Baxi SS; Tchekmedyian V; Grewal RK; Larson SM; Pentlow KS; Haque S; Tuttle RM; Sabra MM; Fish S; Boucai L; Walters J; Ghossein RA; Seshan VE; Ni A; Li D; Knauf JA; Pfister DG; Fagin JA; Ho AL
    J Clin Endocrinol Metab; 2019 May; 104(5):1417-1428. PubMed ID: 30256977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TESC promotes differentiated thyroid cancer development by activating ERK and weakening NIS and radioiodine uptake.
    Guo Y; Cai Y; Song F; Zhu L; Hu Y; Liu Y; Ma W; Ge J; Zeng Q; Ding L; Li L; Zheng G; Ge M
    Endocrine; 2023 Sep; 81(3):503-512. PubMed ID: 37020077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual inhibition of BRAF and MEK increases expression of sodium iodide symporter in patient-derived papillary thyroid cancer cells in┬ávitro.
    Ullmann TM; Liang H; Moore MD; Al-Jamed I; Gray KD; Limberg J; Stefanova D; Buicko JL; Finnerty B; Beninato T; Zarnegar R; Min IM; Fahey TJ
    Surgery; 2020 Jan; 167(1):56-63. PubMed ID: 31585718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.